TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Recursion Pharmaceuticals ( (RXRX) ) just unveiled an update.
On December 8, 2025, Recursion Pharmaceuticals announced positive results from the Phase 1b/2 TUPELO trial of REC-4881, an investigational MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial demonstrated rapid and durable reductions in polyp burden, with 75% of patients showing improvement after 12 weeks of treatment, and 82% maintaining reductions 12 weeks post-treatment. These findings are significant given the lack of approved therapies for FAP, a condition with a high risk of colorectal cancer. The results validate Recursion’s AI-driven approach and suggest REC-4881 could offer a non-surgical treatment option, potentially impacting the company’s market positioning and providing hope for patients with FAP.
The most recent analyst rating on (RXRX) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Recursion Pharmaceuticals stock, see the RXRX Stock Forecast page.
Spark’s Take on RXRX Stock
According to Spark, TipRanks’ AI Analyst, RXRX is a Neutral.
Recursion Pharmaceuticals’ overall stock score is primarily impacted by its financial challenges, including declining revenues and persistent losses. While the company benefits from a strong cash position and strategic partnerships, the bearish technical indicators and negative valuation metrics weigh heavily on the score. Positive developments from corporate events and earnings call provide some support, but the financial instability remains a significant concern.
To see Spark’s full report on RXRX stock, click here.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals is a clinical-stage TechBio company focused on decoding biology to radically improve lives. The company leverages its AI-driven platform, Recursion OS, to discover and develop novel therapeutics, particularly targeting diseases with no approved pharmacotherapy options.
Average Trading Volume: 43,295,886
Technical Sentiment Signal: Sell
Current Market Cap: $2.45B
See more insights into RXRX stock on TipRanks’ Stock Analysis page.